REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS

被引：0
|
作者：
Abdallah, K. [1 ]
Kiani, P. [1 ]
Huys, I [1 ]
Claes, K. [1 ]
Simoens, S. [1 ]
机构：
[1] Katholieke Univ Leuven, B-3000 Leuven, Vbr, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PNS53
引用
收藏
页码：S771 / S771
页数：1
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF DRUGS: SYSTEMATIC REVIEW
    Faleiros, D.
    Alvares, J.
    Almeida, A. M.
    Araujo, V. E.
    Andrade, E., I
    Acurcio, F. D.
    Guerra Junior, A. A.
    VALUE IN HEALTH, 2015, 18 (07) : A813 - A813
  • [22] BENCHMARKING OF BUDGET IMPACT RESULTS: AN UPDATED SYSTEMATIC REVIEW OF US BUDGET IMPACT ANALYSES
    Liu, R.
    Botteman, M.
    VALUE IN HEALTH, 2023, 26 (06) : S398 - S399
  • [23] INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS
    Rousseau, B.
    Poinas, A.
    Oliver, L.
    Collings, H.
    VALUE IN HEALTH, 2017, 20 (09) : A695 - A696
  • [24] THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS
    Forte, L.
    Malmberg, C.
    Mann, K.
    Jupe, K.
    Chow, G.
    Lech, R. A.
    Kulik, R.
    VALUE IN HEALTH, 2019, 22 : S855 - S855
  • [25] IS THE SCOPE OF COSTS CONSIDERED IN BUDGET IMPACT ANALYSES FOR ANTICANCER DRUGS RATIONAL? A SYSTEMATIC REVIEW AND COMPARATIVE STUDY
    Ma, Y.
    Li, Y. X.
    Ma, A. X.
    Li, H. C.
    VALUE IN HEALTH, 2022, 25 (07) : S414 - S414
  • [26] Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
    Ma, Yue
    Li, Yuxin
    Ma, Aixia
    Li, Hongchao
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [27] SYSTEMATIC REVIEW AND BENCHMARKING OF US BUDGET IMPACT ANALYSES
    Waldeck, M.
    Liu, R.
    Kumar, V. M.
    Botteman, M.
    VALUE IN HEALTH, 2019, 22 : S295 - S295
  • [28] WHY MOST BUDGET IMPACT ANALYSES OF MEDICINES ARE NOT ACCURATE? QUALITY OF BUDGET IMPACT ANALYSIS NEEDS TO BE IMPROVED
    Hsu, J. C.
    Ho, M.
    Tsai, T.
    Wu, M.
    VALUE IN HEALTH, 2018, 21 : S112 - S112
  • [29] Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
    Schlander, Michael
    Adarkwah, Charles Christian
    Gandjour, Afschin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (01) : 171 - 179
  • [30] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
    William V. Padula
    Sonal Parasrampuria
    Mariana P. Socal
    Rena M. Conti
    Gerard F. Anderson
    PharmacoEconomics, 2020, 38 : 1115 - 1121
12345